nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—DRD3—Parkinson's disease	0.174	0.229	CbGaD
Methotrimeprazine—DRD1—Parkinson's disease	0.171	0.225	CbGaD
Methotrimeprazine—DRD2—Parkinson's disease	0.121	0.159	CbGaD
Methotrimeprazine—CYP2E1—Parkinson's disease	0.116	0.153	CbGaD
Methotrimeprazine—HTR2A—Parkinson's disease	0.0932	0.123	CbGaD
Methotrimeprazine—CYP2D6—Parkinson's disease	0.0853	0.112	CbGaD
Methotrimeprazine—DRD3—telencephalic ventricle—Parkinson's disease	0.00402	0.0519	CbGeAlD
Methotrimeprazine—HTR2A—enteric nervous system—Parkinson's disease	0.00358	0.0462	CbGeAlD
Methotrimeprazine—DRD1—telencephalic ventricle—Parkinson's disease	0.00288	0.0371	CbGeAlD
Methotrimeprazine—HTR2A—myenteric nerve plexus—Parkinson's disease	0.00271	0.035	CbGeAlD
Methotrimeprazine—HTR2A—locus ceruleus—Parkinson's disease	0.00236	0.0305	CbGeAlD
Methotrimeprazine—HTR2C—telencephalic ventricle—Parkinson's disease	0.00223	0.0288	CbGeAlD
Methotrimeprazine—HTR2A—cerebellar cortex—Parkinson's disease	0.00193	0.0249	CbGeAlD
Methotrimeprazine—HTR2A—sympathetic nervous system—Parkinson's disease	0.00187	0.0241	CbGeAlD
Methotrimeprazine—DRD1—nerve—Parkinson's disease	0.00181	0.0234	CbGeAlD
Methotrimeprazine—DRD2—telencephalic ventricle—Parkinson's disease	0.0017	0.0219	CbGeAlD
Methotrimeprazine—HTR2A—pons—Parkinson's disease	0.00136	0.0176	CbGeAlD
Methotrimeprazine—HTR2A—autonomic nervous system—Parkinson's disease	0.00126	0.0162	CbGeAlD
Methotrimeprazine—HTR2A—telencephalic ventricle—Parkinson's disease	0.00112	0.0145	CbGeAlD
Methotrimeprazine—DRD2—nerve—Parkinson's disease	0.00107	0.0138	CbGeAlD
Methotrimeprazine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00107	0.0138	CbGeAlD
Methotrimeprazine—DRD5—forebrain—Parkinson's disease	0.000983	0.0127	CbGeAlD
Methotrimeprazine—HTR2A—peripheral nervous system—Parkinson's disease	0.000906	0.0117	CbGeAlD
Methotrimeprazine—ADRA1A—hindbrain—Parkinson's disease	0.000819	0.0106	CbGeAlD
Methotrimeprazine—DRD2—hindbrain—Parkinson's disease	0.000802	0.0104	CbGeAlD
Methotrimeprazine—ADRA1D—forebrain—Parkinson's disease	0.000788	0.0102	CbGeAlD
Methotrimeprazine—DRD1—brainstem—Parkinson's disease	0.000778	0.01	CbGeAlD
Methotrimeprazine—DRD1—forebrain—Parkinson's disease	0.000751	0.0097	CbGeAlD
Methotrimeprazine—HTR2A—nerve—Parkinson's disease	0.000707	0.00912	CbGeAlD
Methotrimeprazine—CHRM4—head—Parkinson's disease	0.000646	0.00834	CbGeAlD
Methotrimeprazine—DRD4—brain—Parkinson's disease	0.000619	0.00799	CbGeAlD
Methotrimeprazine—CHRM4—nervous system—Parkinson's disease	0.000613	0.00791	CbGeAlD
Methotrimeprazine—CHRM2—forebrain—Parkinson's disease	0.000606	0.00782	CbGeAlD
Methotrimeprazine—HTR2C—brainstem—Parkinson's disease	0.000605	0.00781	CbGeAlD
Methotrimeprazine—DRD3—head—Parkinson's disease	0.000601	0.00775	CbGeAlD
Methotrimeprazine—CHRM4—central nervous system—Parkinson's disease	0.00059	0.00761	CbGeAlD
Methotrimeprazine—HTR2C—forebrain—Parkinson's disease	0.000584	0.00753	CbGeAlD
Methotrimeprazine—DRD3—nervous system—Parkinson's disease	0.00057	0.00735	CbGeAlD
Methotrimeprazine—DRD5—head—Parkinson's disease	0.000563	0.00727	CbGeAlD
Methotrimeprazine—CHRM1—forebrain—Parkinson's disease	0.000551	0.00711	CbGeAlD
Methotrimeprazine—DRD3—central nervous system—Parkinson's disease	0.000548	0.00708	CbGeAlD
Methotrimeprazine—DRD5—nervous system—Parkinson's disease	0.000534	0.00689	CbGeAlD
Methotrimeprazine—HTR2A—hindbrain—Parkinson's disease	0.000529	0.00683	CbGeAlD
Methotrimeprazine—DRD5—central nervous system—Parkinson's disease	0.000514	0.00663	CbGeAlD
Methotrimeprazine—CHRM2—cardiovascular system—Parkinson's disease	0.000512	0.00661	CbGeAlD
Methotrimeprazine—CHRM5—head—Parkinson's disease	0.000505	0.00652	CbGeAlD
Methotrimeprazine—DRD1—midbrain—Parkinson's disease	0.000496	0.0064	CbGeAlD
Methotrimeprazine—CHRM3—forebrain—Parkinson's disease	0.000493	0.00637	CbGeAlD
Methotrimeprazine—CYP2D6—hindbrain—Parkinson's disease	0.000482	0.00622	CbGeAlD
Methotrimeprazine—CHRM5—nervous system—Parkinson's disease	0.000479	0.00618	CbGeAlD
Methotrimeprazine—ADRA1A—brainstem—Parkinson's disease	0.000469	0.00606	CbGeAlD
Methotrimeprazine—CHRM4—brain—Parkinson's disease	0.000468	0.00604	CbGeAlD
Methotrimeprazine—CHRM1—cardiovascular system—Parkinson's disease	0.000466	0.00602	CbGeAlD
Methotrimeprazine—ADRA1B—head—Parkinson's disease	0.000462	0.00596	CbGeAlD
Methotrimeprazine—CHRM5—central nervous system—Parkinson's disease	0.000461	0.00595	CbGeAlD
Methotrimeprazine—DRD2—brainstem—Parkinson's disease	0.00046	0.00594	CbGeAlD
Methotrimeprazine—ADRA1A—forebrain—Parkinson's disease	0.000453	0.00585	CbGeAlD
Methotrimeprazine—ADRA1D—head—Parkinson's disease	0.000451	0.00583	CbGeAlD
Methotrimeprazine—DRD2—forebrain—Parkinson's disease	0.000444	0.00573	CbGeAlD
Methotrimeprazine—ADRA1B—nervous system—Parkinson's disease	0.000438	0.00565	CbGeAlD
Methotrimeprazine—DRD3—brain—Parkinson's disease	0.000435	0.00562	CbGeAlD
Methotrimeprazine—DRD1—head—Parkinson's disease	0.00043	0.00555	CbGeAlD
Methotrimeprazine—ADRA1D—nervous system—Parkinson's disease	0.000428	0.00552	CbGeAlD
Methotrimeprazine—HTR2C—medulla oblongata—Parkinson's disease	0.000422	0.00544	CbGeAlD
Methotrimeprazine—ADRA1B—central nervous system—Parkinson's disease	0.000421	0.00544	CbGeAlD
Methotrimeprazine—ADRA1D—central nervous system—Parkinson's disease	0.000412	0.00532	CbGeAlD
Methotrimeprazine—DRD5—brain—Parkinson's disease	0.000408	0.00527	CbGeAlD
Methotrimeprazine—DRD1—nervous system—Parkinson's disease	0.000408	0.00526	CbGeAlD
Methotrimeprazine—DRD1—central nervous system—Parkinson's disease	0.000393	0.00507	CbGeAlD
Methotrimeprazine—HTR2C—midbrain—Parkinson's disease	0.000385	0.00497	CbGeAlD
Methotrimeprazine—ADRA1A—cardiovascular system—Parkinson's disease	0.000383	0.00494	CbGeAlD
Methotrimeprazine—HTR2C—spinal cord—Parkinson's disease	0.000376	0.00485	CbGeAlD
Methotrimeprazine—CHRM5—brain—Parkinson's disease	0.000366	0.00472	CbGeAlD
Methotrimeprazine—HRH1—forebrain—Parkinson's disease	0.000351	0.00452	CbGeAlD
Methotrimeprazine—CHRM2—head—Parkinson's disease	0.000347	0.00448	CbGeAlD
Methotrimeprazine—ADRA2A—forebrain—Parkinson's disease	0.000344	0.00444	CbGeAlD
Methotrimeprazine—ADRA1B—brain—Parkinson's disease	0.000334	0.00432	CbGeAlD
Methotrimeprazine—HTR2C—head—Parkinson's disease	0.000334	0.00431	CbGeAlD
Methotrimeprazine—HTR2A—embryo—Parkinson's disease	0.000331	0.00427	CbGeAlD
Methotrimeprazine—CHRM2—nervous system—Parkinson's disease	0.000329	0.00424	CbGeAlD
Methotrimeprazine—ADRA1D—brain—Parkinson's disease	0.000327	0.00422	CbGeAlD
Methotrimeprazine—HTR2C—nervous system—Parkinson's disease	0.000317	0.00409	CbGeAlD
Methotrimeprazine—CHRM2—central nervous system—Parkinson's disease	0.000316	0.00409	CbGeAlD
Methotrimeprazine—CHRM1—head—Parkinson's disease	0.000316	0.00407	CbGeAlD
Methotrimeprazine—ADRA2C—medulla oblongata—Parkinson's disease	0.000312	0.00402	CbGeAlD
Methotrimeprazine—DRD1—brain—Parkinson's disease	0.000312	0.00402	CbGeAlD
Methotrimeprazine—HTR2C—central nervous system—Parkinson's disease	0.000305	0.00394	CbGeAlD
Methotrimeprazine—HTR2A—brainstem—Parkinson's disease	0.000303	0.00392	CbGeAlD
Methotrimeprazine—CHRM1—nervous system—Parkinson's disease	0.000299	0.00386	CbGeAlD
Methotrimeprazine—DRD2—midbrain—Parkinson's disease	0.000293	0.00378	CbGeAlD
Methotrimeprazine—HTR2A—forebrain—Parkinson's disease	0.000293	0.00378	CbGeAlD
Methotrimeprazine—CHRM1—central nervous system—Parkinson's disease	0.000288	0.00372	CbGeAlD
Methotrimeprazine—ADRA2C—midbrain—Parkinson's disease	0.000285	0.00368	CbGeAlD
Methotrimeprazine—CYP2E1—cardiovascular system—Parkinson's disease	0.000285	0.00368	CbGeAlD
Methotrimeprazine—CHRM3—head—Parkinson's disease	0.000282	0.00365	CbGeAlD
Methotrimeprazine—ADRA2C—spinal cord—Parkinson's disease	0.000278	0.00359	CbGeAlD
Methotrimeprazine—CYP2D6—brainstem—Parkinson's disease	0.000276	0.00357	CbGeAlD
Methotrimeprazine—CHRM3—nervous system—Parkinson's disease	0.000268	0.00346	CbGeAlD
Methotrimeprazine—CYP2D6—forebrain—Parkinson's disease	0.000267	0.00344	CbGeAlD
Methotrimeprazine—ADRA1A—head—Parkinson's disease	0.000259	0.00335	CbGeAlD
Methotrimeprazine—CHRM3—central nervous system—Parkinson's disease	0.000258	0.00333	CbGeAlD
Methotrimeprazine—DRD2—head—Parkinson's disease	0.000254	0.00328	CbGeAlD
Methotrimeprazine—CHRM2—brain—Parkinson's disease	0.000251	0.00324	CbGeAlD
Methotrimeprazine—ADRA2A—medulla oblongata—Parkinson's disease	0.000249	0.00321	CbGeAlD
Methotrimeprazine—HTR2A—cardiovascular system—Parkinson's disease	0.000248	0.0032	CbGeAlD
Methotrimeprazine—ADRA2C—head—Parkinson's disease	0.000247	0.00319	CbGeAlD
Methotrimeprazine—ADRA1A—nervous system—Parkinson's disease	0.000246	0.00317	CbGeAlD
Methotrimeprazine—CYP2E1—medulla oblongata—Parkinson's disease	0.000243	0.00314	CbGeAlD
Methotrimeprazine—HTR2C—brain—Parkinson's disease	0.000242	0.00313	CbGeAlD
Methotrimeprazine—DRD2—nervous system—Parkinson's disease	0.000241	0.00311	CbGeAlD
Methotrimeprazine—ADRA1A—central nervous system—Parkinson's disease	0.000237	0.00306	CbGeAlD
Methotrimeprazine—ADRA2C—nervous system—Parkinson's disease	0.000234	0.00302	CbGeAlD
Methotrimeprazine—DRD2—central nervous system—Parkinson's disease	0.000232	0.00299	CbGeAlD
Methotrimeprazine—ADRA1A—cerebellum—Parkinson's disease	0.000231	0.00299	CbGeAlD
Methotrimeprazine—Acetophenazine—DRD1—Parkinson's disease	0.000229	0.0309	CrCbGaD
Methotrimeprazine—CHRM1—brain—Parkinson's disease	0.000229	0.00295	CbGeAlD
Methotrimeprazine—ADRA2A—midbrain—Parkinson's disease	0.000227	0.00293	CbGeAlD
Methotrimeprazine—DRD2—cerebellum—Parkinson's disease	0.000227	0.00293	CbGeAlD
Methotrimeprazine—ADRA2C—central nervous system—Parkinson's disease	0.000226	0.00291	CbGeAlD
Methotrimeprazine—ADRA2A—spinal cord—Parkinson's disease	0.000222	0.00286	CbGeAlD
Methotrimeprazine—ADRA2C—cerebellum—Parkinson's disease	0.00022	0.00285	CbGeAlD
Methotrimeprazine—CYP2E1—spinal cord—Parkinson's disease	0.000217	0.0028	CbGeAlD
Methotrimeprazine—HTR2A—medulla oblongata—Parkinson's disease	0.000212	0.00273	CbGeAlD
Methotrimeprazine—CHRM3—brain—Parkinson's disease	0.000205	0.00264	CbGeAlD
Methotrimeprazine—Propericiazine—DRD1—Parkinson's disease	0.000202	0.0273	CrCbGaD
Methotrimeprazine—HRH1—head—Parkinson's disease	0.000201	0.00259	CbGeAlD
Methotrimeprazine—ADRA2A—head—Parkinson's disease	0.000197	0.00254	CbGeAlD
Methotrimeprazine—HTR2A—midbrain—Parkinson's disease	0.000193	0.0025	CbGeAlD
Methotrimeprazine—CYP2E1—head—Parkinson's disease	0.000193	0.00249	CbGeAlD
Methotrimeprazine—HRH1—nervous system—Parkinson's disease	0.00019	0.00246	CbGeAlD
Methotrimeprazine—HTR2A—spinal cord—Parkinson's disease	0.000189	0.00243	CbGeAlD
Methotrimeprazine—ADRA1A—brain—Parkinson's disease	0.000188	0.00243	CbGeAlD
Methotrimeprazine—ADRA2A—nervous system—Parkinson's disease	0.000187	0.00241	CbGeAlD
Methotrimeprazine—DRD2—brain—Parkinson's disease	0.000184	0.00238	CbGeAlD
Methotrimeprazine—HRH1—central nervous system—Parkinson's disease	0.000183	0.00236	CbGeAlD
Methotrimeprazine—CYP2E1—nervous system—Parkinson's disease	0.000183	0.00236	CbGeAlD
Methotrimeprazine—ADRA2A—central nervous system—Parkinson's disease	0.00018	0.00232	CbGeAlD
Methotrimeprazine—ADRA2C—brain—Parkinson's disease	0.000179	0.00231	CbGeAlD
Methotrimeprazine—CYP2E1—central nervous system—Parkinson's disease	0.000176	0.00227	CbGeAlD
Methotrimeprazine—ADRA2A—cerebellum—Parkinson's disease	0.000176	0.00227	CbGeAlD
Methotrimeprazine—CYP2E1—cerebellum—Parkinson's disease	0.000172	0.00222	CbGeAlD
Methotrimeprazine—HTR2A—head—Parkinson's disease	0.000168	0.00216	CbGeAlD
Methotrimeprazine—Acetophenazine—DRD2—Parkinson's disease	0.000162	0.0218	CrCbGaD
Methotrimeprazine—HTR2A—nervous system—Parkinson's disease	0.000159	0.00205	CbGeAlD
Methotrimeprazine—HTR2A—central nervous system—Parkinson's disease	0.000153	0.00198	CbGeAlD
Methotrimeprazine—CYP2D6—head—Parkinson's disease	0.000153	0.00197	CbGeAlD
Methotrimeprazine—HTR2A—cerebellum—Parkinson's disease	0.00015	0.00193	CbGeAlD
Methotrimeprazine—HRH1—brain—Parkinson's disease	0.000145	0.00188	CbGeAlD
Methotrimeprazine—CYP2D6—nervous system—Parkinson's disease	0.000145	0.00187	CbGeAlD
Methotrimeprazine—ADRA2A—brain—Parkinson's disease	0.000143	0.00184	CbGeAlD
Methotrimeprazine—Triflupromazine—DRD1—Parkinson's disease	0.000141	0.019	CrCbGaD
Methotrimeprazine—CYP2E1—brain—Parkinson's disease	0.00014	0.0018	CbGeAlD
Methotrimeprazine—CYP2D6—central nervous system—Parkinson's disease	0.000139	0.0018	CbGeAlD
Methotrimeprazine—CYP2D6—cerebellum—Parkinson's disease	0.000136	0.00176	CbGeAlD
Methotrimeprazine—Clomipramine—GSTP1—Parkinson's disease	0.000131	0.0177	CrCbGaD
Methotrimeprazine—Acepromazine—DRD1—Parkinson's disease	0.00013	0.0176	CrCbGaD
Methotrimeprazine—Thioproperazine—DRD1—Parkinson's disease	0.000127	0.0172	CrCbGaD
Methotrimeprazine—Mesoridazine—DRD3—Parkinson's disease	0.000126	0.017	CrCbGaD
Methotrimeprazine—Pipotiazine—DRD1—Parkinson's disease	0.000125	0.0169	CrCbGaD
Methotrimeprazine—Mepyramine—CYP2D6—Parkinson's disease	0.000122	0.0165	CrCbGaD
Methotrimeprazine—Prochlorperazine—DRD3—Parkinson's disease	0.000122	0.0164	CrCbGaD
Methotrimeprazine—HTR2A—brain—Parkinson's disease	0.000121	0.00157	CbGeAlD
Methotrimeprazine—CYP2D6—brain—Parkinson's disease	0.000111	0.00143	CbGeAlD
Methotrimeprazine—Cyamemazine—HTR2A—Parkinson's disease	0.00011	0.0149	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD3—Parkinson's disease	0.00011	0.0149	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD1—Parkinson's disease	0.000108	0.0146	CrCbGaD
Methotrimeprazine—Acepromazine—HTR1A—Parkinson's disease	0.000108	0.0146	CrCbGaD
Methotrimeprazine—Thioproperazine—HTR1A—Parkinson's disease	0.000106	0.0142	CrCbGaD
Methotrimeprazine—Propiomazine—DRD1—Parkinson's disease	0.000104	0.014	CrCbGaD
Methotrimeprazine—Pipotiazine—HTR1A—Parkinson's disease	0.000104	0.014	CrCbGaD
Methotrimeprazine—Mesoridazine—HTR1A—Parkinson's disease	0.000103	0.0138	CrCbGaD
Methotrimeprazine—Thioridazine—HTR7—Parkinson's disease	0.000101	0.0136	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD3—Parkinson's disease	0.0001	0.0135	CrCbGaD
Methotrimeprazine—Triflupromazine—DRD2—Parkinson's disease	9.91e-05	0.0134	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD1—Parkinson's disease	9.84e-05	0.0133	CrCbGaD
Methotrimeprazine—Thioridazine—DRD1—Parkinson's disease	9.31e-05	0.0126	CrCbGaD
Methotrimeprazine—Perphenazine—HTR7—Parkinson's disease	9.26e-05	0.0125	CrCbGaD
Methotrimeprazine—Acepromazine—DRD2—Parkinson's disease	9.17e-05	0.0124	CrCbGaD
Methotrimeprazine—Fluphenazine—HTR1A—Parkinson's disease	8.98e-05	0.0121	CrCbGaD
Methotrimeprazine—Thioproperazine—DRD2—Parkinson's disease	8.96e-05	0.0121	CrCbGaD
Methotrimeprazine—Pipotiazine—DRD2—Parkinson's disease	8.82e-05	0.0119	CrCbGaD
Methotrimeprazine—Mequitazine—CYP2D6—Parkinson's disease	8.76e-05	0.0118	CrCbGaD
Methotrimeprazine—Mesoridazine—DRD2—Parkinson's disease	8.7e-05	0.0117	CrCbGaD
Methotrimeprazine—Trimipramine—SLC6A3—Parkinson's disease	8.62e-05	0.0116	CrCbGaD
Methotrimeprazine—Perphenazine—DRD1—Parkinson's disease	8.55e-05	0.0115	CrCbGaD
Methotrimeprazine—Prochlorperazine—DRD2—Parkinson's disease	8.43e-05	0.0114	CrCbGaD
Methotrimeprazine—Diltiazem—CYP2D6—Parkinson's disease	7.86e-05	0.0106	CrCbGaD
Methotrimeprazine—Thioridazine—HTR1A—Parkinson's disease	7.73e-05	0.0104	CrCbGaD
Methotrimeprazine—Promazine—DRD1—Parkinson's disease	7.71e-05	0.0104	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD2—Parkinson's disease	7.62e-05	0.0103	CrCbGaD
Methotrimeprazine—Trimipramine—HTR1A—Parkinson's disease	7.55e-05	0.0102	CrCbGaD
Methotrimeprazine—Chlorpromazine—HTR7—Parkinson's disease	7.35e-05	0.00992	CrCbGaD
Methotrimeprazine—Fluphenazine—CYP2E1—Parkinson's disease	7.34e-05	0.0099	CrCbGaD
Methotrimeprazine—Propiomazine—DRD2—Parkinson's disease	7.33e-05	0.00989	CrCbGaD
Methotrimeprazine—Imipramine—HTR7—Parkinson's disease	7.31e-05	0.00986	CrCbGaD
Methotrimeprazine—Trifluoperazine—HTR1A—Parkinson's disease	7.18e-05	0.00968	CrCbGaD
Methotrimeprazine—Perphenazine—HTR1A—Parkinson's disease	7.1e-05	0.00958	CrCbGaD
Methotrimeprazine—Acepromazine—HTR2A—Parkinson's disease	7.09e-05	0.00956	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD2—Parkinson's disease	6.94e-05	0.00936	CrCbGaD
Methotrimeprazine—Thioproperazine—HTR2A—Parkinson's disease	6.93e-05	0.00935	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD3—Parkinson's disease	6.91e-05	0.00932	CrCbGaD
Methotrimeprazine—Pipotiazine—HTR2A—Parkinson's disease	6.81e-05	0.00919	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD1—Parkinson's disease	6.78e-05	0.00915	CrCbGaD
Methotrimeprazine—Mesoridazine—HTR2A—Parkinson's disease	6.72e-05	0.00908	CrCbGaD
Methotrimeprazine—Thioridazine—DRD2—Parkinson's disease	6.57e-05	0.00886	CrCbGaD
Methotrimeprazine—Trimipramine—DRD2—Parkinson's disease	6.41e-05	0.00865	CrCbGaD
Methotrimeprazine—Imipramine—SLC6A3—Parkinson's disease	6.4e-05	0.00863	CrCbGaD
Methotrimeprazine—Thioridazine—CYP2E1—Parkinson's disease	6.32e-05	0.00853	CrCbGaD
Methotrimeprazine—Pipotiazine—CYP2D6—Parkinson's disease	6.23e-05	0.00841	CrCbGaD
Methotrimeprazine—Promethazine—DRD2—Parkinson's disease	6.17e-05	0.00833	CrCbGaD
Methotrimeprazine—Mesoridazine—CYP2D6—Parkinson's disease	6.15e-05	0.0083	CrCbGaD
Methotrimeprazine—Trifluoperazine—DRD2—Parkinson's disease	6.09e-05	0.00822	CrCbGaD
Methotrimeprazine—Perphenazine—DRD2—Parkinson's disease	6.03e-05	0.00813	CrCbGaD
Methotrimeprazine—Prochlorperazine—CYP2D6—Parkinson's disease	5.95e-05	0.00804	CrCbGaD
Methotrimeprazine—Fluphenazine—HTR2A—Parkinson's disease	5.89e-05	0.00795	CrCbGaD
Methotrimeprazine—Propiomazine—HTR2A—Parkinson's disease	5.66e-05	0.00764	CrCbGaD
Methotrimeprazine—Chlorpromazine—HTR1A—Parkinson's disease	5.63e-05	0.0076	CrCbGaD
Methotrimeprazine—Diltiazem—ABCB1—Parkinson's disease	5.61e-05	0.00757	CrCbGaD
Methotrimeprazine—Imipramine—HTR1A—Parkinson's disease	5.6e-05	0.00756	CrCbGaD
Methotrimeprazine—Promazine—DRD2—Parkinson's disease	5.43e-05	0.00733	CrCbGaD
Methotrimeprazine—Clomipramine—HTR2A—Parkinson's disease	5.39e-05	0.00727	CrCbGaD
Methotrimeprazine—Fluphenazine—CYP2D6—Parkinson's disease	5.39e-05	0.00727	CrCbGaD
Methotrimeprazine—Chlorprothixene—HTR2A—Parkinson's disease	5.36e-05	0.00724	CrCbGaD
Methotrimeprazine—Thioridazine—HTR2A—Parkinson's disease	5.07e-05	0.00685	CrCbGaD
Methotrimeprazine—Triflupromazine—ABCB1—Parkinson's disease	5e-05	0.00675	CrCbGaD
Methotrimeprazine—Trimipramine—HTR2A—Parkinson's disease	4.96e-05	0.00669	CrCbGaD
Methotrimeprazine—Clomipramine—CYP2D6—Parkinson's disease	4.93e-05	0.00665	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD2—Parkinson's disease	4.78e-05	0.00645	CrCbGaD
Methotrimeprazine—Promethazine—HTR2A—Parkinson's disease	4.77e-05	0.00644	CrCbGaD
Methotrimeprazine—Imipramine—DRD2—Parkinson's disease	4.76e-05	0.00642	CrCbGaD
Methotrimeprazine—Trifluoperazine—HTR2A—Parkinson's disease	4.71e-05	0.00635	CrCbGaD
Methotrimeprazine—Perphenazine—HTR2A—Parkinson's disease	4.66e-05	0.00628	CrCbGaD
Methotrimeprazine—Thioridazine—CYP2D6—Parkinson's disease	4.64e-05	0.00626	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP2E1—Parkinson's disease	4.6e-05	0.00621	CrCbGaD
Methotrimeprazine—Imipramine—CYP2E1—Parkinson's disease	4.58e-05	0.00618	CrCbGaD
Methotrimeprazine—Trimipramine—CYP2D6—Parkinson's disease	4.53e-05	0.00612	CrCbGaD
Methotrimeprazine—Promethazine—CYP2D6—Parkinson's disease	4.36e-05	0.00589	CrCbGaD
Methotrimeprazine—Perphenazine—CYP2D6—Parkinson's disease	4.26e-05	0.00575	CrCbGaD
Methotrimeprazine—Promazine—HTR2A—Parkinson's disease	4.2e-05	0.00566	CrCbGaD
Methotrimeprazine—Fluphenazine—ABCB1—Parkinson's disease	3.85e-05	0.00519	CrCbGaD
Methotrimeprazine—Chlorpromazine—HTR2A—Parkinson's disease	3.69e-05	0.00499	CrCbGaD
Methotrimeprazine—Imipramine—HTR2A—Parkinson's disease	3.68e-05	0.00496	CrCbGaD
Methotrimeprazine—Clomipramine—ABCB1—Parkinson's disease	3.52e-05	0.00475	CrCbGaD
Methotrimeprazine—Chlorprothixene—ABCB1—Parkinson's disease	3.5e-05	0.00473	CrCbGaD
Methotrimeprazine—Chlorpromazine—CYP2D6—Parkinson's disease	3.38e-05	0.00456	CrCbGaD
Methotrimeprazine—Imipramine—CYP2D6—Parkinson's disease	3.36e-05	0.00454	CrCbGaD
Methotrimeprazine—Trimipramine—ABCB1—Parkinson's disease	3.24e-05	0.00437	CrCbGaD
Methotrimeprazine—Promethazine—ABCB1—Parkinson's disease	3.12e-05	0.0042	CrCbGaD
Methotrimeprazine—Trifluoperazine—ABCB1—Parkinson's disease	3.07e-05	0.00415	CrCbGaD
Methotrimeprazine—Chlorpromazine—ABCB1—Parkinson's disease	2.41e-05	0.00326	CrCbGaD
Methotrimeprazine—Imipramine—ABCB1—Parkinson's disease	2.4e-05	0.00324	CrCbGaD
Methotrimeprazine—CHRM3—Signaling Pathways—DRD2—Parkinson's disease	6.47e-06	4.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HTR7—Parkinson's disease	6.47e-06	4.19e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—NGF—Parkinson's disease	6.46e-06	4.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HTR2A—Parkinson's disease	6.46e-06	4.18e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—DRD2—Parkinson's disease	6.41e-06	4.15e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HTR7—Parkinson's disease	6.41e-06	4.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HTR7—Parkinson's disease	6.39e-06	4.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—DRD2—Parkinson's disease	6.39e-06	4.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—NGF—Parkinson's disease	6.38e-06	4.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—NGF—Parkinson's disease	6.38e-06	4.13e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—CYCS—Parkinson's disease	6.37e-06	4.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—APOE—Parkinson's disease	6.36e-06	4.11e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IGF1R—Parkinson's disease	6.34e-06	4.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—ABCB1—Parkinson's disease	6.31e-06	4.09e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IGF2—Parkinson's disease	6.3e-06	4.08e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—APOE—Parkinson's disease	6.27e-06	4.06e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EDN1—Parkinson's disease	6.27e-06	4.06e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HTR2A—Parkinson's disease	6.15e-06	3.98e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—COMT—Parkinson's disease	6.15e-06	3.98e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	6.13e-06	3.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IGF2—Parkinson's disease	6.13e-06	3.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—GSTM1—Parkinson's disease	6.13e-06	3.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	6.12e-06	3.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—MTHFR—Parkinson's disease	6.12e-06	3.96e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—MAOA—Parkinson's disease	6.1e-06	3.95e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IGF1R—Parkinson's disease	6.09e-06	3.94e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—PLA2G6—Parkinson's disease	6.08e-06	3.94e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HTR2A—Parkinson's disease	6.07e-06	3.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HTR2A—Parkinson's disease	6.07e-06	3.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	6.03e-06	3.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IGF2—Parkinson's disease	6.03e-06	3.9e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MAOB—Parkinson's disease	6.02e-06	3.9e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EDN1—Parkinson's disease	6.02e-06	3.9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—APOE—Parkinson's disease	6e-06	3.89e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	5.94e-06	3.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	5.94e-06	3.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IGF1R—Parkinson's disease	5.92e-06	3.84e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—GPX1—Parkinson's disease	5.87e-06	3.8e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EDN1—Parkinson's disease	5.85e-06	3.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IGF1R—Parkinson's disease	5.83e-06	3.77e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	5.79e-06	3.75e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EDN1—Parkinson's disease	5.76e-06	3.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—NGF—Parkinson's disease	5.76e-06	3.73e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Parkinson's disease	5.73e-06	3.71e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—APOE—Parkinson's disease	5.72e-06	3.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—APOE—Parkinson's disease	5.69e-06	3.69e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—APOE—Parkinson's disease	5.65e-06	3.65e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—APOE—Parkinson's disease	5.65e-06	3.65e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—COMT—Parkinson's disease	5.64e-06	3.65e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	5.62e-06	3.64e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—GSTP1—Parkinson's disease	5.62e-06	3.64e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—MAOA—Parkinson's disease	5.6e-06	3.63e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IGF2—Parkinson's disease	5.56e-06	3.6e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—HMOX1—Parkinson's disease	5.54e-06	3.59e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—NGF—Parkinson's disease	5.53e-06	3.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HTR2A—Parkinson's disease	5.48e-06	3.55e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—CASP3—Parkinson's disease	5.48e-06	3.55e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IGF2—Parkinson's disease	5.47e-06	3.54e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IGF2—Parkinson's disease	5.46e-06	3.53e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling by GPCR—IL6—Parkinson's disease	5.44e-06	3.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IGF2—Parkinson's disease	5.44e-06	3.52e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—INS—Parkinson's disease	5.43e-06	3.52e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IGF2—Parkinson's disease	5.42e-06	3.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—MTHFR—Parkinson's disease	5.41e-06	3.5e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—GPX1—Parkinson's disease	5.38e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—NGF—Parkinson's disease	5.38e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IGF1R—Parkinson's disease	5.38e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IGF2—Parkinson's disease	5.37e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IGF2—Parkinson's disease	5.36e-06	3.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—INS—Parkinson's disease	5.36e-06	3.47e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—ABCB1—Parkinson's disease	5.32e-06	3.44e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EDN1—Parkinson's disease	5.31e-06	3.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—NGF—Parkinson's disease	5.29e-06	3.43e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IGF1R—Parkinson's disease	5.29e-06	3.42e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IGF1R—Parkinson's disease	5.28e-06	3.42e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HTR2A—Parkinson's disease	5.26e-06	3.41e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IGF1R—Parkinson's disease	5.26e-06	3.41e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IGF1R—Parkinson's disease	5.24e-06	3.4e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EDN1—Parkinson's disease	5.23e-06	3.38e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EDN1—Parkinson's disease	5.21e-06	3.38e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EDN1—Parkinson's disease	5.2e-06	3.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IGF1R—Parkinson's disease	5.19e-06	3.36e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CTGF—Parkinson's disease	5.19e-06	3.36e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EDN1—Parkinson's disease	5.18e-06	3.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IGF1R—Parkinson's disease	5.18e-06	3.35e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—GSTM1—Parkinson's disease	5.16e-06	3.34e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EDN1—Parkinson's disease	5.13e-06	3.32e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—INS—Parkinson's disease	5.13e-06	3.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HTR2A—Parkinson's disease	5.12e-06	3.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EDN1—Parkinson's disease	5.12e-06	3.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—APOE—Parkinson's disease	5.1e-06	3.3e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HTR2A—Parkinson's disease	5.04e-06	3.26e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—APOE—Parkinson's disease	5.04e-06	3.26e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—MAPK8—Parkinson's disease	5.03e-06	3.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	4.98e-06	3.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	4.97e-06	3.22e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—GPX1—Parkinson's disease	4.94e-06	3.2e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—APOE—Parkinson's disease	4.89e-06	3.17e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—INS—Parkinson's disease	4.89e-06	3.16e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—NGF—Parkinson's disease	4.88e-06	3.16e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—INS—Parkinson's disease	4.86e-06	3.15e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CYP2E1—Parkinson's disease	4.83e-06	3.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—INS—Parkinson's disease	4.82e-06	3.12e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—INS—Parkinson's disease	4.82e-06	3.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	4.81e-06	3.12e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—NGF—Parkinson's disease	4.8e-06	3.11e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—NGF—Parkinson's disease	4.79e-06	3.1e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—NQO1—Parkinson's disease	4.78e-06	3.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—NGF—Parkinson's disease	4.78e-06	3.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—NGF—Parkinson's disease	4.76e-06	3.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—APOE—Parkinson's disease	4.76e-06	3.08e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	4.75e-06	3.08e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—NGF—Parkinson's disease	4.72e-06	3.05e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—TH—Parkinson's disease	4.71e-06	3.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—NGF—Parkinson's disease	4.7e-06	3.04e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—APOE—Parkinson's disease	4.69e-06	3.03e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HTR2A—Parkinson's disease	4.65e-06	3.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—APOE—Parkinson's disease	4.62e-06	2.99e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HTR2A—Parkinson's disease	4.56e-06	2.95e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—MTHFR—Parkinson's disease	4.56e-06	2.95e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HTR2A—Parkinson's disease	4.55e-06	2.94e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HTR2A—Parkinson's disease	4.53e-06	2.93e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CYCS—Parkinson's disease	4.52e-06	2.93e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HTR2A—Parkinson's disease	4.49e-06	2.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HTR2A—Parkinson's disease	4.48e-06	2.9e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CYP2D6—Parkinson's disease	4.48e-06	2.9e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CTGF—Parkinson's disease	4.39e-06	2.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	4.37e-06	2.83e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—INS—Parkinson's disease	4.35e-06	2.82e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—APOE—Parkinson's disease	4.32e-06	2.8e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—INS—Parkinson's disease	4.31e-06	2.79e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—APOE—Parkinson's disease	4.25e-06	2.75e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—APOE—Parkinson's disease	4.25e-06	2.75e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—APOE—Parkinson's disease	4.24e-06	2.75e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—APOE—Parkinson's disease	4.23e-06	2.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—APOE—Parkinson's disease	4.21e-06	2.73e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—INS—Parkinson's disease	4.18e-06	2.71e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—APOE—Parkinson's disease	4.17e-06	2.7e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—APOE—Parkinson's disease	4.16e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	4.16e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CYP2E1—Parkinson's disease	4.09e-06	2.65e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—INS—Parkinson's disease	4.07e-06	2.63e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—NQO1—Parkinson's disease	4.05e-06	2.62e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—CASP3—Parkinson's disease	4.04e-06	2.62e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—IL6—Parkinson's disease	4.02e-06	2.6e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—COMT—Parkinson's disease	4e-06	2.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—INS—Parkinson's disease	4e-06	2.59e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—TH—Parkinson's disease	3.99e-06	2.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—CASP3—Parkinson's disease	3.99e-06	2.58e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—GSTP1—Parkinson's disease	3.99e-06	2.58e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—MAOA—Parkinson's disease	3.98e-06	2.57e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—IL6—Parkinson's disease	3.96e-06	2.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—INS—Parkinson's disease	3.95e-06	2.56e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—HMOX1—Parkinson's disease	3.93e-06	2.54e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	3.87e-06	2.5e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CYCS—Parkinson's disease	3.83e-06	2.48e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—CASP3—Parkinson's disease	3.82e-06	2.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—IL6—Parkinson's disease	3.79e-06	2.46e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ABCB1—Parkinson's disease	3.77e-06	2.44e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—MAPK8—Parkinson's disease	3.72e-06	2.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—INS—Parkinson's disease	3.69e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—MAPK8—Parkinson's disease	3.67e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—GSTM1—Parkinson's disease	3.66e-06	2.37e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—CASP3—Parkinson's disease	3.64e-06	2.36e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—INS—Parkinson's disease	3.63e-06	2.35e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—INS—Parkinson's disease	3.63e-06	2.35e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—INS—Parkinson's disease	3.62e-06	2.35e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—IL6—Parkinson's disease	3.62e-06	2.34e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—INS—Parkinson's disease	3.61e-06	2.34e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—INS—Parkinson's disease	3.6e-06	2.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—CASP3—Parkinson's disease	3.59e-06	2.32e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—CASP3—Parkinson's disease	3.59e-06	2.32e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—IL6—Parkinson's disease	3.57e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—IL6—Parkinson's disease	3.57e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—INS—Parkinson's disease	3.57e-06	2.31e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—INS—Parkinson's disease	3.56e-06	2.3e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—MAPK8—Parkinson's disease	3.51e-06	2.27e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—GPX1—Parkinson's disease	3.51e-06	2.27e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—COMT—Parkinson's disease	3.39e-06	2.2e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GSTP1—Parkinson's disease	3.38e-06	2.19e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MAOA—Parkinson's disease	3.37e-06	2.18e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—MAPK8—Parkinson's disease	3.34e-06	2.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—HMOX1—Parkinson's disease	3.33e-06	2.16e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	3.3e-06	2.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—MAPK8—Parkinson's disease	3.3e-06	2.14e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—MAPK8—Parkinson's disease	3.3e-06	2.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—CASP3—Parkinson's disease	3.24e-06	2.1e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—MTHFR—Parkinson's disease	3.24e-06	2.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—IL6—Parkinson's disease	3.22e-06	2.09e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—IL6—Parkinson's disease	3.21e-06	2.08e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ABCB1—Parkinson's disease	3.2e-06	2.07e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—CASP3—Parkinson's disease	3.11e-06	2.02e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GSTM1—Parkinson's disease	3.1e-06	2.01e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—IL6—Parkinson's disease	3.09e-06	2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—CASP3—Parkinson's disease	3.03e-06	1.96e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—APOE—Parkinson's disease	3.01e-06	1.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—IL6—Parkinson's disease	3.01e-06	1.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—CASP3—Parkinson's disease	2.98e-06	1.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—MAPK8—Parkinson's disease	2.98e-06	1.93e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—GPX1—Parkinson's disease	2.97e-06	1.92e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—IL6—Parkinson's disease	2.96e-06	1.92e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—MAPK8—Parkinson's disease	2.86e-06	1.85e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—MAPK8—Parkinson's disease	2.78e-06	1.8e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—CASP3—Parkinson's disease	2.75e-06	1.78e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MTHFR—Parkinson's disease	2.74e-06	1.78e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—MAPK8—Parkinson's disease	2.74e-06	1.77e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—IL6—Parkinson's disease	2.73e-06	1.77e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—CASP3—Parkinson's disease	2.7e-06	1.75e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—CASP3—Parkinson's disease	2.7e-06	1.75e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—CASP3—Parkinson's disease	2.69e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—IL6—Parkinson's disease	2.69e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—CASP3—Parkinson's disease	2.68e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—IL6—Parkinson's disease	2.68e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—IL6—Parkinson's disease	2.67e-06	1.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—IL6—Parkinson's disease	2.66e-06	1.72e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—CASP3—Parkinson's disease	2.65e-06	1.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—CASP3—Parkinson's disease	2.65e-06	1.71e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—IL6—Parkinson's disease	2.64e-06	1.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—IL6—Parkinson's disease	2.63e-06	1.7e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—INS—Parkinson's disease	2.57e-06	1.67e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—APOE—Parkinson's disease	2.55e-06	1.65e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—MAPK8—Parkinson's disease	2.53e-06	1.63e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—MAPK8—Parkinson's disease	2.48e-06	1.61e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—MAPK8—Parkinson's disease	2.48e-06	1.61e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—MAPK8—Parkinson's disease	2.47e-06	1.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—MAPK8—Parkinson's disease	2.46e-06	1.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	2.46e-06	1.59e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	2.44e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—MAPK8—Parkinson's disease	2.44e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—MAPK8—Parkinson's disease	2.43e-06	1.58e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—IL6—Parkinson's disease	2.37e-06	1.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—IL6—Parkinson's disease	2.34e-06	1.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	2.26e-06	1.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—IL6—Parkinson's disease	2.24e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—INS—Parkinson's disease	2.18e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—IL6—Parkinson's disease	2.14e-06	1.38e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—IL6—Parkinson's disease	2.11e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—IL6—Parkinson's disease	2.11e-06	1.36e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—IL6—Parkinson's disease	1.9e-06	1.23e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—IL6—Parkinson's disease	1.83e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—IL6—Parkinson's disease	1.78e-06	1.15e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—IL6—Parkinson's disease	1.75e-06	1.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—IL6—Parkinson's disease	1.61e-06	1.04e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—IL6—Parkinson's disease	1.59e-06	1.03e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—IL6—Parkinson's disease	1.58e-06	1.03e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—IL6—Parkinson's disease	1.58e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—IL6—Parkinson's disease	1.57e-06	1.02e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—IL6—Parkinson's disease	1.56e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—IL6—Parkinson's disease	1.55e-06	1.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	1.44e-06	9.35e-06	CbGpPWpGaD
